<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020462</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068505</org_study_id>
    <secondary_id>NCI-01-C-0069</secondary_id>
    <nct_id>NCT00020462</nct_id>
    <nct_alias>NCT00008996</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma</brief_title>
  <official_title>Active Specific Immunotherapy for Follicular Lymphomas With Liposomes Containing Tumor-Derived Antigen and IL-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune&#xD;
      response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more&#xD;
      effective treatment for follicular lymphoma .&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus interleukin-2 in&#xD;
      treating patients who have stage III, stage IV, or recurrent follicular lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the safety of immunotherapy with autologous tumor cell vaccine and interleukin-2&#xD;
           in patients with stage III, IV, or recurrent follicular lymphoma.&#xD;
&#xD;
        -  Determine the clinical response of patients treated with this regimen.&#xD;
&#xD;
        -  Assess the immune response of patients treated with this vaccine.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prior therapy (no&#xD;
      prior biologic therapy or chemotherapy for lymphoma vs prior prednisone, doxorubicin,&#xD;
      cyclophosphamide, and etoposide (PACE) chemotherapy). Patients without prior therapy are&#xD;
      further stratified according to accessibility of lymph nodes (easily accessible (stratum Ia)&#xD;
      vs not easily accessible (stratum Ib)).&#xD;
&#xD;
      All patients undergo lymph node biopsy to obtain tissue for vaccine manufacture. Treatment&#xD;
      begins approximately 1 month after biopsy.&#xD;
&#xD;
        -  Stratum Ia: Patients receive autologous tumor cell vaccine and interleukin-2 (IL-2)&#xD;
           intranodally and subcutaneously (SC) on day 1.&#xD;
&#xD;
        -  Stratum Ib and stratum II: Patients receive autologous tumor cell vaccine and IL-2 SC on&#xD;
           day 1.&#xD;
&#xD;
      Treatment in each stratum continues every 4 weeks for a maximum of 5 courses in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 1 and 4 months, every 3 months for 1 year, and every 6 months&#xD;
      thereafter until relapse or progression of disease.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients (10 per stratum) will be accrued for this study&#xD;
      within 1.5-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven follicular center cell lymphoma with surface immunoglobulin (Ig)&#xD;
             M, G, or A phenotype&#xD;
&#xD;
               -  Grade I (follicular small cleaved cell)&#xD;
&#xD;
               -  Grade II (follicular mixed small and large cell)&#xD;
&#xD;
               -  Grade III (follicular large cell)&#xD;
&#xD;
          -  Stage III, IV, or recurrent disease&#xD;
&#xD;
          -  Previously untreated with chemotherapy or monoclonal antibody therapy OR&#xD;
&#xD;
          -  Recurrent, residual disease or progressive disease after prior prednisone,&#xD;
             doxorubicin, cyclophosphamide, and etoposide (PACE) chemotherapy&#xD;
&#xD;
          -  Peripheral lymph node of at least 2 cm and accessible for biopsy/harvest&#xD;
&#xD;
          -  No primary or secondary CNS lymphoma&#xD;
&#xD;
          -  Must not have any of the following:&#xD;
&#xD;
               -  Rapidly progressing lymphadenopathy&#xD;
&#xD;
               -  Bone marrow failure secondary to lymphoma&#xD;
&#xD;
               -  B symptoms&#xD;
&#xD;
               -  Neurovascular or organ compromise secondary to lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 1 year&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  ALT/AST no greater than 3.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL unless secondary to Gilbert's disease&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other prior or concurrent malignancy except curatively treated squamous cell or&#xD;
             basal cell skin cancer or effectively treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No medical or psychiatric condition that would preclude study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent biologic therapy for lymphoma&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior PACE chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior steroid treatment&#xD;
&#xD;
          -  Less than 2 months of prior prednisone&#xD;
&#xD;
          -  No concurrent endocrine therapy for lymphoma&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy to no more than 1 site allowed&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Lymph node biopsy performed within past month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sattva S. Neelapu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicine Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Neelapu SS, Gause BL, Harvey L, Lee ST, Frye AR, Horton J, Robb RJ, Popescu MC, Kwak LW. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood. 2007 Jun 15;109(12):5160-3. Epub 2007 Mar 5.</citation>
    <PMID>17339422</PMID>
  </results_reference>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

